Journal Watch · Journal of Medicinal Chemistry · 2026

Discovery of Potent and Orally Bioavailable Diaminoquinazoline-Derived mRNA Decapping Scavenger (DcpS) Enzyme Inhibitors for Treatment of Solid Tumors.

Finally, compound 17 demonstrates oral dose-dependent efficacy in two solid tumor xenograft models, A253 and EBC-1, highlighting the promise of DcpS as a novel target in FHIT low/deficient solid tumors.

Scholz SO, Dudnik AS, Vasilopoulos A et al.Journal of Medicinal Chemistry3 min readPharma relevance 70/100

DOI: 10.1021/acs.jmedchem.6c01711PMID: 42593929Study type: preclinical (animal / model) study

TL;DR

Finally, compound 17 demonstrates oral dose-dependent efficacy in two solid tumor xenograft models, A253 and EBC-1, highlighting the promise of DcpS as a novel target in FHIT low/deficient solid tumors.

Key findings

  • Compound 17 possesses superior levels of potency in NSCLC A549 cell line relative to known inhibitors and demonstrates excellent selectivity against DcpS-insensitive cell lines, high levels of bioavailability in preclinical species, and mitigated hERG liabilities.
  • Finally, compound 17 demonstrates oral dose-dependent efficacy in two solid tumor xenograft models, A253 and EBC-1, highlighting the promise of DcpS as a novel target in FHIT low/deficient solid tumors.

What they did

We have discovered a novel DcpS inhibitor, compound 17, which has a differentiated binding mode relative to known inhibitors, engaging the second nucleotide-binding domain of the mRNA cap substrate.

Full abstract (original)

Background: Decapping Scavenger (DcpS) enzyme, a pyrophosphatase involved in mRNA regulation via mRNA cap degradation, has been identified as a promising oncology target in fragile histidine triad (FHIT) deficient cancers such as AML and GBM but remains underexplored in broader solid tumor indications.

What they did: We have discovered a novel DcpS inhibitor, compound 17, which has a differentiated binding mode relative to known inhibitors, engaging the second nucleotide-binding domain of the mRNA cap substrate.

Results & conclusions: Compound 17 possesses superior levels of potency in NSCLC A549 cell line relative to known inhibitors and demonstrates excellent selectivity against DcpS-insensitive cell lines, high levels of bioavailability in preclinical species, and mitigated hERG liabilities. Finally, compound 17 demonstrates oral dose-dependent efficacy in two solid tumor xenograft models, A253 and EBC-1, highlighting the promise of DcpS as a novel target in FHIT low/deficient solid tumors.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c01711 · PubMed 42593929.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

Finally, compound 17 demonstrates oral dose-dependent efficacy in two solid tumor xenograft models, A253 and EBC-1, highlighting the promise of DcpS as a novel target in FHIT low/deficient solid tumors.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. We have discovered a novel DcpS inhibitor, compound 17, which has a differentiated binding mode relative to known inhibitors, engaging the second nucleotide-binding domain of the mRNA cap substrate.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c01711. PubMed ID: 42593929. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Scholz SO, Dudnik AS, Vasilopoulos A et al.. Discovery of Potent and Orally Bioavailable Diaminoquinazoline-Derived mRNA Decapping Scavenger (DcpS) Enzyme Inhibitors for Treatment of Solid Tumors.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c01711.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-potent-and-orally-bioavailable-diaminoquinazoline-derived-m-c01711/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides